Disease relevance of oxoiron

• Assessment of Bone Marrow Angiogenesis in Patients with Acute Myeloid Leukemia by Using Contrast-enhanced MR Imaging with Clinically Approved Iron Oxides: Initial Experience [1].
• MATERIALS AND METHODS: Iron oxides with different particle sizes (hydrodynamic diameters, 21, 33, 46, and 65 nm) were bolus injected intravenously at three doses (10, 20, and 40 micromol per kilogram body weight) [2].
• Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer [3].
• Iron oxide nanoparticles have been proposed for an increasing number of biomedical applications although in vitro toxicity depending on the particles coating has been evidenced [4].
• Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow [5].

High impact information on oxoiron

• Iron oxide nanoparticles and liposomes coated with this tumor-homing peptide accumulate in tumor vessels, where they induce additional local clotting, thereby producing new binding sites for more particles [6].
• Iron oxide contrast agents have been employed extensively in anesthetized rodents to enhance fMRI sensitivity and to study the physiology of cerebral blood volume (CBV) in relation to blood oxygen level-dependent (BOLD) signal following neuronal activation [7].
• Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages [8].
• Iron oxide nanoparticle-labeled rat smooth muscle cells: cardiac MR imaging for cell graft monitoring and quantitation [9].
• Iron oxide exposure upregulated Tf mRNA in bronchial and alveolar epithelium, macrophages, and BALT, but protein was not significantly increased [10].

Biological context of oxoiron

• Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism [11].
• Iron oxide and cobalt oxide aerosols were judged suitable for inhalation studies in calves, and cobalt oxide was selected for pulmonary clearance studies due to the low background content of cobalt in lung tissue [12].
• Iron oxide deposition did not bring about significant changes in cell types or numbers of AM lavaged, AM viabilities, or the plastic substrate adherence characteristics of the AM [13].

Anatomical context of oxoiron

• Iron oxide nanoparticles can therefore be used as a marker for the long-term noninvasive MR tracking of implanted stem cells [14].
• BACKGROUND AND PURPOSE: Iron oxide-based contrast agents have been investigated as more specific MR imaging agents for central nervous system (CNS) inflammation [15].
• Iron oxide was the least effective and the matched susceptibility mixture was the most effective for the intestine, which has traditionally been the most difficult region of the GI tract to visualize clearly [16].
• Iron oxide (positive Perls blue staining) was observed in Kupffer cells after injection of medium and large SPIO particles, and also in hepatocytes after injection of small SPIO particles [17].
• CONCLUSIONS: Iron oxide in the preocular tear film is taken up preferentially by conjunctival lymphoid tissue, supporting the hypothesis that mammalian conjunctival lymphoid follicles may participate in the acquired immune response to pathogens in the preocular tear film [18].

Associations of oxoiron with other chemical compounds

• Electrospray ionization in combination with Fourier transform ion cyclotron resonance spectrometry is used to prepare and characterize at a molecular level high-valent oxoiron intermediates formed in the reaction of [(TPFPP)Fe(III)]Cl (TPFPP= meso-tetrakis(pentafluorophenyl)porphinato dianion) (1-Cl) with H(2)O(2) in methanol [19].
• Indirect evidence for the formation of six-coordinate oxoiron (IV) tetramesitylporphyrin complexes FeIV = O(tmp*)X (X=Cl-, Br-) by m-CPBA oxidation of FeX(tmp) (X=Cl-, Br-) in butyronitrile at - 78 degrees C was also obtained by Mössbauer spectroscopy [20].
• Iron oxide nanocomposites of magnetic particles coated with zirconia were used as affinity probes to selectively concentrate phosphopeptides from tryptic digests of alpha- and beta-caseins, milk, and egg white to exemplify the enrichment of phosphopeptides from complex samples [21].
• Iron oxide magnetic nanoparticles were incorporated into the hydrogel systems by polymerizing mixtures of the nanoparticles and monomer solutions [22].

Gene context of oxoiron

• LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases [23].
• Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery [24].
• Iron oxide particles per se did not affect mRNA levels of cyp1a1 but only enhanced BaP-mediated increases of CYP1A1 protein levels and activity [25].

Analytical, diagnostic and therapeutic context of oxoiron

• Iron oxide was given intravenously in concentrations of 0 (control group), 2.5, 5, 10, and 20 mumol/kg to three rats in each concentration group [26].
• Iron oxide particles were administered in an IV drip infusion over 30 min [27].
• Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable [28].
• Iron oxide (Fe2O3) was identified and characterized by surface area, X-ray diffractometry, and FTIR analyses [29].
• CMR 2005: 9.06: Iron oxide nanoparticles as a cell labeling contrast agent for non-invasive long-term cell therapy monitoring by MRI: an abdominal aortic aneurysm model [30].

References